{name}
{subtitle}
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~43 mi. (Gauting, Germany, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~57 mi. (Munich, Germany, +130 more cities)
facility
Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)
drug
BCG solution, +1 more drug
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
city
~57 mi. (Munich, Germany, +3 more cities)
facility
Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum
biomarker
ER Positive, +2 more biomarkers
drug
hormone therapy, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
city
~57 mi. (Munich, Germany, +37 more cities)
facility
Klinikum Rechts der Isar der Technischen Universitat Munchen
biomarker
ER Negative, +2 more biomarkers
drug
ladiratuzumab vedotin, +1 more drug
drug type
chemotherapy, +2 more types
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~62 mi. (Ulm, Germany, +150 more cities)
facility
Universitaetsklinikum Ulm ( Site 0402)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~62 mi. (Ulm, Germany, +127 more cities)
facility
Universitaetsklinikum Ulm ( Site 2102)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type